CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®
Dong-A ST stated that its R&D expertise has been reaffirmed by the positive CHMP opinion, following the FDA approval for ...
GlobalData on MSN5d
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s
Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...
FiercePharma5d
Johnson & Johnson eases initial Stelara blows with strong Darzalex, Carvykti growth
Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...
Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth
J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and ...
BioSpace5d
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
dermatologyadvisor2d
FDA Approves Stelara Biosimilar Imuldosa for Some Inflammatory Conditions
The FDA has approved Imuldosa, a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.
FiercePharma6d
On road to crowded Crohn's disease market, Lilly's Omvoh bests J&J's Stelara in head-to-head study
On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...
Drug Store News5d
FDA approves Dong-A ST’s Stelara biosimilar
Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...
devdiscourse2d
Imuldosa® Gains CHMP Approval as Biosimilar to Stelara® in Europe
Imuldosa®, a biosimilar to Stelara®, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), paving the way for its authorization in Europe. Developed by Accord ...
Zacks.com on MSN3d
J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?
On Oct. 15, J&J JNJ announced strong third-quarter results, beating estimates for both earnings and sales. The Innovative ...
J&J quarterly earnings beat expectations, shows progress on talc liabilities
Johnson and Johnson reported stronger-than-expected third-quarter earnings, driven by surging sales of cancer medicine ...
Accord Healthcare receives positive CHMP opinion for IMULDOSA, ustekinumab biosimilar to Stelara
According to the EMA CHMP summary of positive opinion, DMB-3115 is highly similar to the reference product Stelara (ustekinumab) and has demonstrated comparable quality, safety and efficacy to Stelara ...